Key Events This Week
8 Jun: New 52-week high at Rs.71.00
9 Jun: All-time high reached Rs.78.94
12 Jun: New 52-week and all-time high at Rs.84.7
12 Jun: Stock closes week at Rs.82.62 (+26.14%)
8 June 2026: Breakout to New 52-Week High at Rs.71
Novelix Pharmaceuticals Ltd began the week on a strong note, hitting a new 52-week high of Rs.71. The stock surged 6.32% to close at Rs.69.64, significantly outperforming the Sensex which declined 1.33% to 34,673.90. This breakout was supported by a robust intraday gain of 8.4% and a gap up of 8.32% at the open, signalling strong buying interest. The stock’s price action was bolstered by sustained gains over the prior four days, cumulatively up 32.9%, and trading above all major moving averages. Despite a bearish broader market, Novelix’s resilience highlighted its relative strength within the retailing sector.
9 June 2026: All-Time High at Rs.78.94 Amidst Volatility
The momentum continued on 9 June as Novelix Pharmaceuticals Ltd reached an all-time high of Rs.78.94, closing at Rs.75.90 with an 8.99% gain. This represented a 13.35% intraday rise from the day’s low of Rs.68.23. The stock outperformed its sector peers by 10.95%, while the Sensex gained a modest 0.88%. The session was marked by heightened volatility with a 7.27% intraday range, yet the stock maintained strength above key moving averages. This day marked the fifth consecutive session of gains, delivering a total return of 48.09% over that period, underscoring sustained investor confidence and technical bullishness.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
12 June 2026: New 52-Week and All-Time High at Rs.84.7
On the final trading day of the week, Novelix Pharmaceuticals Ltd surged to a new 52-week and all-time high of Rs.84.7, closing at Rs.82.62 with a 3.95% daily gain. The stock outperformed the Sensex’s 2.20% rise, reflecting a strong relative performance. This marked the eighth consecutive day of gains, delivering a cumulative return of 57.58% over this period. Technical indicators remained bullish, with the stock trading above all key moving averages and supported by positive MACD, Bollinger Bands, and KST signals on weekly and monthly charts. Despite a bearish weekly RSI, the overall momentum remained robust. The stock’s premium valuation multiples and improved Mojo rating to Hold underscore its elevated market standing.
Weekly Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-08 | Rs.69.64 | +6.32% | 34,673.90 | -1.33% |
| 2026-06-09 | Rs.75.90 | +8.99% | 34,979.26 | +0.88% |
| 2026-06-10 | Rs.76.14 | +0.32% | 34,766.59 | -0.61% |
| 2026-06-11 | Rs.79.48 | +4.39% | 34,580.95 | -0.53% |
| 2026-06-12 | Rs.82.62 | +3.95% | 35,342.50 | +2.20% |
Valuation and Rating Developments
Throughout the week, Novelix Pharmaceuticals Ltd’s valuation profile shifted notably. The stock’s price-to-earnings ratio rose to 75x trailing twelve months, with price-to-book value at 7.50x and enterprise value multiples (EV/EBITDA and EV/EBIT) exceeding 54x and 56x respectively. These elevated multiples reflect a premium pricing environment, driven by strong price momentum and investor optimism. The company’s Mojo Score stands at 65.0, with a Hold rating upgraded from Sell earlier in January 2026, signalling improved market perception despite valuation concerns. The micro-cap status adds volatility considerations, but the stock’s consistent outperformance and technical strength have underpinned this rating shift.
Novelix Pharmaceuticals Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Key Takeaways
Positive Signals: The stock’s eight-day winning streak and 26.14% weekly gain highlight strong investor demand and technical momentum. Multiple new 52-week and all-time highs demonstrate robust price appreciation. The upgrade to a Hold rating by MarketsMOJO reflects improved fundamentals and market confidence. Trading volumes surged significantly, supporting liquidity and price strength. The stock’s performance vastly outpaced the Sensex, which rose only 0.57% over the week.
Cautionary Notes: Elevated valuation multiples suggest the stock is trading at a premium, with a P/E of 75x and high EV multiples. Some technical indicators, such as the weekly RSI, signal potential short-term overbought conditions. The company’s modest return on capital employed and return on equity metrics indicate profitability challenges. As a micro-cap stock, Novelix carries inherent volatility and risk, warranting close monitoring of earnings and operational trends.
Conclusion
Novelix Pharmaceuticals Ltd’s performance during the week of 8 to 12 June 2026 was characterised by exceptional price gains, multiple record highs, and an upgraded market rating. The stock’s 26.14% rise dwarfed the Sensex’s modest 0.57% gain, underscoring its strong relative strength amid a cautious broader market. Technical indicators largely support the bullish momentum, while valuation metrics reflect a premium pricing environment. Investors should weigh the impressive price appreciation and improved rating against valuation risks and the company’s micro-cap volatility. Overall, Novelix Pharmaceuticals Ltd’s recent trajectory marks a significant phase in its market journey, driven by sustained buying interest and positive sentiment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
